Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Niagen Bioscience, Inc. Director's Dealing 2023

May 30, 2023

32418_dirs_2023-05-30_d4ec4132-92e1-492e-8350-3e624ba6c158.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2023-05-25

Reporting Person: Rubin Steven D (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-05-25 Common Stock P 7000 $1.46 Acquired 7000 Direct